摘要
幽门螺杆菌感染(Hp-I)是世界上许多国家大多数人群中发现的流行病,并且导致大量的胃肠道疾病。同样,神经退行性疾病如阿尔茨海默氏病,帕金森病,多发性硬化症或定义为眼部阿尔茨海默病的青光眼与公共卫生负担很重,并且是导致残疾的主要原因。新出现的证据表明Hp-I可能与神经退行性疾病有关。此外,Hp-I可能是代谢综合征(MetS)的预测指标。 Hp-I及其相关的MetS可能诱发胃肠道运动障碍性疾病,并伴有全身性并发症,可能包括中枢神经系统神经退行性病变。我们在此探讨Hprelated代谢性胃肠功能障碍在Hprelated神经退行性疾病和胃肠道疾病的分子病理生理学中的新兴作用。通过应用新的相对治疗策略,包括增强Hp根除的新机会,提高对脑病理学中这种Hp-I病理生理学的理解可能带来益处
关键词: 幽门螺杆菌,胃肠运动障碍,阿尔茨海默病,多发性硬化症,青光眼,神经变性。
Current Molecular Medicine
Title:The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration
Volume: 17 Issue: 6
关键词: 幽门螺杆菌,胃肠运动障碍,阿尔茨海默病,多发性硬化症,青光眼,神经变性。
摘要: Helicobacter pylori infection (Hp-I) is a prevalent disorder identified in the majority of the population in many countries around the world and is responsible for substantial gastrointestinal morbidity. Likewise, neurodegenerative diseases such as Alzheimer's disease, Parkinson’s diseases, multiple sclerosis or glaucoma defined as ocular Alzheimer's disease, are associated with a large public health burden and are among the leading causes of disability. Emerging evidences suggest that Hp-I may be associated with neurodegenerative conditions. Moreover, Hp-I could be a predictor of metabolic syndrome (MetS). Hp-I and its related MetS may induce gastrointestinal tract dys-motility disorders with systemic complications possibly including central nervous system neurodegenerative pathologies. We hereby explore the emerging role of Hprelated metabolic gastrointestinal dys-motilities on the molecular pathophysiology of Hprelated neurodegenerative and gastrointestinal disorders. Improving understanding of such Hp-I pathophysiology in brain pathologies may offer benefits by application of new relative therapeutic strategies including novel opportunities toward enhancing Hp eradication.
Export Options
About this article
Cite this article as:
The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration, Current Molecular Medicine 2017; 17 (6) . https://dx.doi.org/10.2174/1566524018666171219094837
DOI https://dx.doi.org/10.2174/1566524018666171219094837 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering
Current Drug Therapy Perioperative Considerations in Patients with Obstructive Sleep Apnea
Current Respiratory Medicine Reviews Hurdles in the Drug Discovery of Cathepsin K Inhibitors
Current Topics in Medicinal Chemistry New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Anti-leishmanial Activity of Gossypium hirsutum L., Ferula assa-foetida L. and Artemisia aucheri Boiss. Extracts by Colorimetric Assay
Anti-Infective Agents Pediatric Chronic Daily Headache
Current Pediatric Reviews Structure-Activity Relationship Studies on Holy Basil (Ocimum sanctum L.) Based Flavonoid Orientin and its Analogue for Cytotoxic Activity in Liver Cancer Cell Line HepG2
Combinatorial Chemistry & High Throughput Screening Peironimev-Plus® in the Treatment of Chronic Inflammation of Tunica Albuginea (Peyronie’s Disease). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Non-Analgesic Effects of Opioids: Opioid-induced Nausea and Vomiting: Mechanisms and Strategies for their Limitation
Current Pharmaceutical Design Hypotensive Agents from Snake Venoms
Current Drug Targets - Cardiovascular & Hematological Disorders Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design Immunotherapy for Food Allergies in Children
Current Pharmaceutical Design Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Prostaglandin E2 Receptors as Potential Bone Anabolic Targets – Selective EP4 Receptor Agonists
Current Molecular Pharmacology Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Current Neuropharmacology Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Psychotropic Medications and the Treatment of Human Prion Diseases
CNS & Neurological Disorders - Drug Targets Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors
Current Aging Science Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews